<DOC>
	<DOCNO>NCT00720928</DOCNO>
	<brief_summary>Objectives : To describe safety efficacy intravitreal flucinolone acetonide implant management patient refractory ocular Behcet 's disease Hypothesis : A descriptive observational study Study design : A 1-year , multi-center ( include four Korean medical center ) observational study</brief_summary>
	<brief_title>Flucinolone Acetonide Implant Treating Refractory Ocular Behcet 's Disease</brief_title>
	<detailed_description>A multi-center , prospective single arm study ass efficacy safety retisert ( intravitreal flucinolone acetonide 0.59 mg ) patient refractory ocular Behcet 's disease . This study conduct 4 site , locate Korea . The number subject expect approximately 15 patient . The medical record patient meet follow inclusion/exclusion criterion collect 1 year implantation .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Males nonpregnant female least 18 year age complete incomplete type Behcet 's disease accord revise diagnostic criterion propose Behcet 's Disease Research Committee Japan 2003 ; typical ocular lesion least , one main symptom two additional symptom . One eyes history recurrent chronic ocular Behcet 's disease affect eye 1 year duration require either systemic corticosteroid equivalent systemic therapy least three month prior enrollment ; OR least 2 subTenon 's injection corticosteroid management uveitis six month prior enrollment ; OR least 2 separate recurrence within six month prior enrollment require either systemic corticosteroid therapy subTenon 's injection corticosteroid At time enrollment implant eye must : ≤ 10 anterior chamber cells/HPF vitreous haze ≤ grade 2 Visual acuity least 1.4 logMAR unit ( Snellen 20/500 ) . Allergy FA component delivery system History posterior segment uveitis accompany vitritis macular edema History iritis vitreous cell vitreous haze Uveitis infectious etiology Vitreous hemorrhage Presence toxoplasmosis scar study eye Peripheral retinal detachment area implantation Media opacity preclude evaluation retina vitreous Uncontrolled increased intraocular pressure ( IOP ) ( &gt; 21mmHg ) time retisert implantation Ocular surgery study eye within 3 month prior enrollment Patients require chronic systemic corticosteroid therapy ( &gt; 15mg prednisone daily ) systemic immunosuppressive therapy manage nonocular disease Patients test positive human immunodeficiency virus Pregnant lactating female Females childbearing potential consider become pregnant course study take effective contraception/precautions avoid pregnancy Patients , physician 's opinion , protocol procedure may pose special risk outweigh potential benefit participate study Patients unlikely comply study protocol likely move lose followup 1 year Patients currently enrol IND investigational study participate IND investigational study within 1 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Behcet 's disease</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>flucinolone acetonide</keyword>
	<keyword>RETISERT</keyword>
</DOC>